This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Fatty Liver Disease and Multi-System Complications - VIRTUAL CONTENT AVAILABLE ON DEMAND
joint with Hepatobiliary Cancers: Pathobiology and Translational Advances - VIRTUAL CONTENT AVAILABLE ON DEMAND
Organizer(s): Jay D. Horton, Morris J. Birnbaum and Hannele Yki-Järvinen
Date: March 22 - 24, 2021
Location: Virtual at your computer. Recorded presentation content is available On Demand.
Sponsored by Merck & Co., Inc. and Novo Nordisk A/S
For important information on the coronavirus, please click here
Summary of Meeting:
Although the frequency of nonalcoholic fatty liver disease (NAFLD) has risen worldwide in parallel with the obesity epidemic, there are still no approved therapies. The more advanced form of the disease, non-alcoholic steatohepatitis (NASH), is associated with progressive fibrosis and an increased risk of hepatocellular carcinoma (HCC). In the last decade, genetic studies have identified new proteins that participate not only in the development of hepatic steatosis, but also disease progression to non-alcoholic steatohepatitis (NASH), cirrhosis, and HCC. Meanwhile, research is starting to emerge describing underlying molecular pathways that mediate alterations in lipid and glucose metabolism, which leads to fat accumulation in liver. Therefore, the goals of this conference are to: 1) Explore the genetic contributions to NAFLD, and how these insights might reveal the sequence of events that cause NASH and cirrhosis; 2) Present data underlying the proposal that the nonalcoholic fatty liver disease (NAFLD) be renamed metabolic (dysfunction) associated fatty liver disease (MAFLD); 3) Clarify the key molecular events in NAFLD and NASH, focusing on pathways that might provide therapeutic opportunities; and 4) Highlight emerging therapies for NASH. This conference comes at an opportunistic time, when several clinical trials are scheduled to conclude, providing critical data to enable scientists to refine research strategies for the future.
Scholarship Deadline: November 1 2020
Abstract Deadline: February 16 2021
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Merck & Co., Inc.Novo Nordisk A/S
We gratefully acknowledge additional support for this conference from:
Mayo Clinic Hepatobiliary SPORE
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 1R13DK129023-01
Funding for this conference was made possible (in part) by 1 R13 DK 129023-01 from NIDDK. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found